UK Adoption of EU Food-Safety Rules Could Reshape the Market
Summarize
United Kingdom (UK) regulators at the Food Standards Agency (FSA) are likely to adopt the lower daily CBD limit recommended by the European Union Food Safety Authority (EFSA) system. This would be followed by a formal agreement that will take effect by the middle of 2027. This change is likely to lead to many UK CBD producers exiting the market because their products will not meet the stricter daily CBD intake recommended limits. The UK FSA has a limit of approximately 10 mg per day, while the EFSA has set a limit of 2 mg per day.
The EFSA has a stricter policy because of its assessment of safety concerns. Neither the 2 mg nor the 10 mg per day limits are currently formal legal standards, but the guidelines play a critical role in how regulators assess the safety of CBD products. If the UK adopts the lower limit, many existing CBD products will not meet it. Products will need to be reformulated, and consumers may no longer consider them effective. This will be costly for CBD producers and retailers, and sales are likely to decrease.
The UK FSA has already made it clear that it plans to switch to a 2 mg daily CBD limit. It is also expected to enter into a formal agreement with the EU. The sanitary and phytosanitary (SPS) agreement with the EU would take effect in mid-2027. The FSA has already told businesses to assume the adoption of the lower daily CBD amount will take effect, and many novel foods applications will not get final approval in time. The products most likely to make it through before the limit change are those already submitted as consortium applications. These applications cover thousands of CBD products.
This means CBD companies must decide whether to continue investing in the approval process or withdraw their applications. The application process is expensive, may require additional studies, requires the preparation of dossiers and more. It is a long application process that the European Industrial Hemp Association has worked to standardize and streamline across the UK and EU.
Many CBD companies are small businesses selling products that would have to be reformulated. The UK system has been criticized for issues like a lack of transparency, delays, unclear timelines, and shifting requirements. Adopting the EU system would likely lead to consolidation in the CBD industry. Large companies and consortia will have the resources necessary to meet regulatory standards, while smaller companies will have to decide if they can continue to compete.
It is too bad that most actions that governments take in the cannabinoid arena seem to harm small CBD brands and make it more difficult for consumers to access effective products. It is unknown how much clinical research will be enough for government agencies to declare a status on CBD safety officially.
Share this post
0